Tests shorter radiotherapy and hormone therapy for high-risk localized prostate cancer
Tests shorter hormone therapy with dose-escalated radiotherapy in adults with prostate cancer.
Plain-language title generated from the registry record
Registry title: Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
Key facts
- Where
- Limassol, CyprusSee the site
- Phase
- Phase 2
Where in Cyprus
- Linac-Pet Scan Opco LimitedLimassol, CyprusTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- German Oncology Center, Cyprus
- Trial code
- NCT06772441EU 2024-510707-11-00
- Record updated
- 15 September 2026
- Original description
The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to the National Comprehensive Cancer Network (NCCN) based on multimodal artificial intelligence (MMAI) classification. All patients will receive (i) a dose escalation to the prostate via HDR brachytherapy (boost), (ii) twelve months of ADT and (iii) extremely hypofractionated RT to the prostate (5 fractions).Read full original descriptionShow less
Prostate-only, Dose-escalated Radiotherapy Plus Concomitant Androgen Deprivation Therapy in Primary Localized, NCCN High Risk and MMAI Classifier Low or Intermediate-risk Prostate Cancer - A Prospective, Single-arm, Phase II Study
The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to the National Comprehensive Cancer Network (NCCN) based on multimodal artificial intelligence (MMAI) classification. All patients will receive (i) a dose escalation to the prostate via HDR brachytherapy (boost), (ii) twelve months of ADT and (iii) extremely hypofractionated RT to the prostate (5 fractions).
This way, patients in the HypoPro trial will receive a prostate-only dose escalation and benefit from shortening of the ADT compared with current guideline recommendations.
Inclusion: Histologically confirmed adenocarcinoma of the prostate (histological confirmation can be based on tissue taken at any time, but a re-biopsy should be considered if the biopsy is more than 12 months old); Primary PCa (in PSMA-PET imaging and multiparametric magnetic resonance imaging (mpMRI); High-risk according to NCCNv4.2023 criteria (cT3a or Grade group 4-5 or PSA > 20 ng/ml); Signed written informed consent for this study; Age >18 years; Previously conducted PSMA-PET/CT, mpMRI or PSMA-PET/MR; MMAI low-/intermediate-risk; ECOG Performance score 0 or 1; IPSS Score ≤15; Prostate biopsy core with the highest ISUP grade available.
Exclusion: Prior radiotherapy to the prostate or pelvis; Prior radical prostatectomy; Prior focal therapy approaches to the prostate; Time gap between the beginning of any systemic therapy, ADT and conduction of PSMA-PET scans is >2 months; PSA >50 ng/ml prior to starting of systemic therapy; Bilateral hip prostheses or any other implants/hardware that would introduce substantial CT artifacts; Prostate surgery (TURP or HOLEP) with a significant tissue cavity or prostate surgery (TURP or HOLEP) within the last 6 months prior to randomization; Any other contraindication to external beam radiotherapy (EBRT) to the pelvis; Participation in any other interventional clinical trial within the last 30 days before the start of this trial; Known or persistent abuse of medication, drugs or alcohol; Evidence of pelvic nodal disease (cN+) in mpMRI and/or PSMA-PET/CT; Evidence of distant metastatic disease (cM+) in mpMRI and/or PSMA-PET/CT; Evidence of cT4 disease in mpMRI and/or PSMA-PET/CT; Medical conditions likely to make radiotherapy inadvisable e.g. acute inflammatory bowel disease, hemiplegia or paraplegia; Previous malignancy within the last 2 years (except basal cell carcinoma or squamous cell carcinoma of the skin), or if previous malignancy is expected to significantly compromise 5 year survival; Patients expected to have severe set up problems (e.g. mental condition); Expected patient survival <5 years; Contraindication to undergo a MRI scan; Contraindication to undergo HDR brachytherapy (brachytherapy not feasible due to large prostate volume, prostate anatomy, tumor in distant seminal vesicles and/or unfit for anaesthesia); Contraindication to Goserelin; Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed; Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial.